Back to Agenda
Session 6: COVID-19 Hot Topics: Rapid Responses of the RWE Community
Session Chair(s)
Marni Hall, PHD, MPH
Vice President and General Manager, Global Regulatory Science and Strategy , IQVIA, United States
Richard Forshee, PHD
Associate Director of Benefit Risk Assessment, OSE, CDER, FDA, United States
This session provides examples of the role RWE plays to inform the pandemic response. Specific use cases including evaluation of the natural history of the disease, comparative studies of therapeutics, and establishment of a near real-time community reporting system. An emphasis will be placed on lessons learned from the need for rapid collaboration and adaptation.
Learning Objective : At the conclusion of this session, participants should be able to:
- List key uses for RWE in the COVID-19 pandemic
- Discuss representative COVID-19 pandemic RWD sources and their strengths and limitations
- Apply lessons learned from collaborative COVID-19 pandemic RWE partnerships to future activities
Speaker(s)
Robert Ball, MD, MPH, MSC
Deputy Director, Office of Surveillance and Epidemiology, CDER, FDA, United States
Speaker
Patrick Ryan
Vice President Observational Health Data Analytics, Janssen Pharmaceuticals, Inc., United States
Speaker
Jeff Allen, PHD
President and Chief Executive Officer, Friends of Cancer Research, United States
Speaker
Nancy Dreyer, MPH, FISPE
Founder, Dreyer Strategies LLC, United States
Speaker
Have an account?